Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q7687250> ?p ?o }
Showing triples 1 to 49 of
49
with 100 triples per page.
- Q7687250 subject Q22572429.
- Q7687250 subject Q52376.
- Q7687250 subject Q8297708.
- Q7687250 subject Q8727262.
- Q7687250 subject Q9454024.
- Q7687250 abstract "Tasimelteon (trade name Hetlioz) is a drug approved by the U.S. Food and Drug Administration (FDA) in January 2014 for the treatment of non-24-hour sleep–wake disorder (also called Non-24, N24 and N24HSWD). In June 2014, the European Medicines Agency accepted an EU filing application for tasimelteon and in July 2015, the drug was approved in Europe for the treatment of non-24-hour sleep-wake rhythm disorder in totally blind adults, but not in the rarer case of non-24 in sighted people.Tasimelteon is a selective agonist for the melatonin receptors MT1 and MT2, similar to other members of the melatonin receptor agonist class of which ramelteon (2005) and agomelatine (2009) were the first approved. As a treatment for N24HSWD, as with melatonin or other melatonin derivatives, the patient may experience improved sleep timing while taking the drug. Reversion to baseline sleep performance occurs within a month of discontinuation.".
- Q7687250 atcPrefix "N05".
- Q7687250 atcSuffix "CH03".
- Q7687250 casNumber "609799-22-6".
- Q7687250 chEBI "79042".
- Q7687250 fdaUniiCode "SHS4PU80D9".
- Q7687250 iupacName "(1R, 2R)-N-[2-(2,3-dihydrobenzofuran-4-yl)cyclopropylmethyl]propanamide".
- Q7687250 pubchem "10220503".
- Q7687250 thumbnail Tasimelteon_2.svg?width=300.
- Q7687250 wikiPageWikiLink Q130146.
- Q7687250 wikiPageWikiLink Q1367466.
- Q7687250 wikiPageWikiLink Q1368197.
- Q7687250 wikiPageWikiLink Q14864419.
- Q7687250 wikiPageWikiLink Q14890102.
- Q7687250 wikiPageWikiLink Q1773215.
- Q7687250 wikiPageWikiLink Q1869874.
- Q7687250 wikiPageWikiLink Q204711.
- Q7687250 wikiPageWikiLink Q22572429.
- Q7687250 wikiPageWikiLink Q3294709.
- Q7687250 wikiPageWikiLink Q389934.
- Q7687250 wikiPageWikiLink Q395229.
- Q7687250 wikiPageWikiLink Q417689.
- Q7687250 wikiPageWikiLink Q431603.
- Q7687250 wikiPageWikiLink Q52376.
- Q7687250 wikiPageWikiLink Q6811647.
- Q7687250 wikiPageWikiLink Q7257343.
- Q7687250 wikiPageWikiLink Q8297708.
- Q7687250 wikiPageWikiLink Q8727262.
- Q7687250 wikiPageWikiLink Q9454024.
- Q7687250 atcPrefix "N05".
- Q7687250 atcSuffix "CH03".
- Q7687250 casNumber "609799".
- Q7687250 chebi "79042".
- Q7687250 iupacName "-N-[2-cyclopropylmethyl]propanamide".
- Q7687250 pubchem "10220503".
- Q7687250 unii "SHS4PU80D9".
- Q7687250 type ChemicalSubstance.
- Q7687250 type Drug.
- Q7687250 type ChemicalObject.
- Q7687250 type Thing.
- Q7687250 type Q8386.
- Q7687250 comment "Tasimelteon (trade name Hetlioz) is a drug approved by the U.S. Food and Drug Administration (FDA) in January 2014 for the treatment of non-24-hour sleep–wake disorder (also called Non-24, N24 and N24HSWD).".
- Q7687250 label "Tasimelteon".
- Q7687250 depiction Tasimelteon_2.svg.